Johnson & Johnson Advances Prostate Cancer Research with New Collaboration

Johnson & Johnson's Janssen unit partners with GI Innovation for a Phase 1b prostate cancer study. Institutional investors increased stakes in Q4 2025, with the stock up 36% in a year.

A new clinical trial partnership signals continued progress in Johnson & Johnson's oncology pipeline. On March 19, the company's Janssen R&D division entered into a clinical supply agreement with the biotechnology firm GI Innovation. The collaboration will focus on a Phase 1b study for metastatic castration-resistant prostate cancer, an aggressive form of the disease where standard treatment options are no longer effective.

Trial Design and Leadership

The study will investigate a novel combination therapy. Researchers will evaluate GI Innovation's experimental drug candidate, GI-102, alongside Johnson & Johnson's bispecific antibody, known as Pasritamig (KLK2-CD3). The core hypothesis is that the two agents may work synergistically to benefit patients who have not responded to prior lines of therapy.

Clinical operations will be conducted at sites in South Korea, including the Asan Medical Center and Severance Hospital, as well as in the United States. Dr. Mark Stein of Columbia University has been appointed as the global coordinating principal investigator for the trial.

Institutional Investor Confidence Remains Strong

Alongside these clinical developments, recent regulatory filings reveal a pattern of growing institutional ownership. During the fourth quarter of 2025, several major investment firms increased their stakes in Johnson & Johnson.

Park National Corp OH expanded its position by 24.3%, bringing its total holding to approximately 118,600 shares. Similarly, GAMMA Investing LLC raised its stake by 13.3%. Overall, institutional investors now control about 69.6% of the company's outstanding shares. This sustained interest from professional money managers may be linked to the stock's robust performance, which has seen it appreciate roughly 36% over the past year, outpacing many industry peers.

Johnson & Johnson continues to return capital to shareholders, maintaining a quarterly dividend of $1.30 per share.